ID: ALA606099

Max Phase: Preclinical

Molecular Formula: C11H14F2N5O7P

Molecular Weight: 397.23

Molecule Type: Small molecule

Representations

Canonical SMILES:  Nc1nc(O)c2ncn(C3O[C@H](COP(=O)(O)C(F)F)[C@@H](O)[C@H]3O)c2n1

Standard InChI:  InChI=1S/C11H14F2N5O7P/c12-10(13)26(22,23)24-1-3-5(19)6(20)9(25-3)18-2-15-4-7(18)16-11(14)17-8(4)21/h2-3,5-6,9-10,19-20H,1H2,(H,22,23)(H3,14,16,17,21)/t3-,5-,6-,9?/m1/s1

Standard InChI Key:  XVLNYMSWVRTVNF-LZGMGDPASA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 397.23

Molecular Weight (Monoisotopic): 397.0599

AlogP: -0.84

#Rotatable Bonds: 5

Polar Surface Area: 186.07

Molecular Species: ACID

HBA: 11

HBD: 5

#RO5 Violations: 1

HBA (Lipinski): 12

HBD (Lipinski): 6

#RO5 Violations (Lipinski): 2

CX Acidic pKa: 0.17

CX Basic pKa: 1.01

CX LogP: -1.82

CX LogD: -3.01

Aromatic Rings: 2

Heavy Atoms: 26

QED Weighted: 0.40

Np Likeness Score: 0.63

References

1. Casara PJ, Jund KC, Clauss A, Nave J, Snyder RD.  (1992)  Synthesis of acid stable 5-o-fluoromethyl phosphonates of nucleosides. Evaluation as inhibitors of reverse transcriptase.,  2  (2): [10.1016/S0960-894X(01)80437-6]

Source

Source(1):

• Scientific Literature